SHARE

Oxis Biotech, Inc., a wholly owned subsidiary unit of OXIS International, Inc. (OTCMKTS:OXIS) confirmed that it retained the Emmes Group to help with the development and implementation of the Company’s business, technology licensing and partnership initiatives and strategies.

Anthony Cataldo, the Chairman and CEO said that he is pleased to again get an opportunity to associate with the Emmes Group, and EVP & Managing Director, Martin Schroeder. He and his colleagues were responsible for assisting the company to discover the cell therapy assets, and designing and implementing the business initiatives and licensing plans which were the foundation of Lion Biotechnologies.

The changes

Oxis subsidiary has retained various industry leading experts as members on scientific advisory board, and in corporate management consultative roles. The management believes that by having a well-seasoned and well-versed group of individuals involved in distinct aspects of the Oxis business model, will help company to successfully execute and record its therapeutic and corporate development goals.

Mr. Cataldo further added that the management goal at Oxis subsidiary is to create a pioneering cancer immunotherapy firm focused on platform technologies such as antibody-drug conjugates, bispecific immune cell engagers, novel small molecule therapeutics, and others.

The significance

The association with The Emmes Group maters a lot as it is a strategy consulting firm assisting firms engaged in the healthcare and technology industries. The associates have more than 50 years of total combined experience. They work in partnership with clients to enhance profits and create lasting economic value. The expertise spans numerous key areas, including technology licensing, corporate finance, strategy consulting, partnerships, business development, market research & modeling, mergers & acquisitions, strategic marketing, and investor due diligence.

In last trading session, the stock price of OXIS declined more than 3% to close the trading session at $0.0301. The decline came at a share volume of 2.29 million compared to average share volume of 4.05 million.

LEAVE A REPLY